rewirebio.iobenchmarks
Benchmark

OncoVI 2026 oncogenicity evaluation study

Published-study grouping of the catalogued evaluation protocols. This grouping does not claim an executable suite, full-paper extraction or independent clinical validation.

5 evaluations · 27 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

5 recorded evaluations, 27 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.

View coverage and remaining gaps across all benchmarks

Results

Results are available, but no reviewed comparison panel is linked in this release.

All evaluations

5 evaluations · 27 results. Different protocols are not a single leaderboard.

Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions
Dataset: ClinVar April 2025 oncogenicity assertions
83% Accuracy
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: ClinVar April 2025 oncogenicity assertions

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions
Dataset: ClinVar April 2025 oncogenicity assertions
81.1% Percent agreement (variant type: missense)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: ClinVar April 2025 oncogenicity assertions

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, missense_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions
Dataset: ClinVar April 2025 oncogenicity assertions
76.1% Percent agreement (gene role: oncogene)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: ClinVar April 2025 oncogenicity assertions

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, oncogene_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions
Dataset: ClinVar April 2025 oncogenicity assertions
84% Recall (class: oncogenic)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: ClinVar April 2025 oncogenicity assertions

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, oncogenic_sensitivity; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions
Dataset: ClinVar April 2025 oncogenicity assertions
87.5% Percent agreement (variant type: truncating)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: ClinVar April 2025 oncogenicity assertions

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, truncating_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions
Dataset: ClinVar April 2025 oncogenicity assertions
85.7% Percent agreement (gene role: tumour suppressor)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: ClinVar April 2025 oncogenicity assertions

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, tsg_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: MTB selected expert reassessment
Dataset: MTB selected expert reassessment
80% Percent agreement (vs expert reassessment)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: MTB selected expert reassessment

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, MTB selected expert reassessment, expert_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: MTB selected expert reassessment
Dataset: MTB selected expert reassessment
22% Percent agreement (prior mtb classification vs expert reassessment)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: MTB selected expert reassessment

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, MTB selected expert reassessment, prior_mtb_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: MTB selected expert reassessment
Dataset: MTB selected expert reassessment
0.7 Correlation (correlation type not stated)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: MTB selected expert reassessment

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Figure 4C, concordant variants only
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Erlangen MTB variants
Dataset: Erlangen MTB variants
43% Percent agreement (class: benign)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Erlangen MTB variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, benign_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Erlangen MTB variants
Dataset: Erlangen MTB variants
78% Percent agreement
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Erlangen MTB variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Erlangen MTB variants
Dataset: Erlangen MTB variants
78.2% Percent agreement (variant type: missense)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Erlangen MTB variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, missense_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Erlangen MTB variants
Dataset: Erlangen MTB variants
82.5% Percent agreement (gene role: oncogene)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Erlangen MTB variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogene_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Erlangen MTB variants
Dataset: Erlangen MTB variants
79% Percent agreement (oncogenic vs pathogenic)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Erlangen MTB variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogenic_vs_pathogenic_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Erlangen MTB variants
Dataset: Erlangen MTB variants
49.4% Percent agreement (variant type: truncating)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Erlangen MTB variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, truncating_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Erlangen MTB variants
Dataset: Erlangen MTB variants
76% Percent agreement (gene role: tumour suppressor)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Erlangen MTB variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, tsg_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Erlangen MTB variants
Dataset: Erlangen MTB variants
97% Percent agreement (class: VUS)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Erlangen MTB variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, vus_concordance; subgroup values correspond to Supplemental Table S6
Configuration: Historical Erlangen MTB protein-function interpretationProtocol: OncoVI three-class assessment: MTB selected expert reassessment
Dataset: MTB selected expert reassessment
34% Percent agreement (vs expert reassessment)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Historical MTB agreement with expert oncogenicity reassessment

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, validation data set, paragraph ending 46/135; Figure 4A
Configuration: Historical Erlangen MTB protein-function interpretationProtocol: OncoVI three-class assessment: MTB selected expert reassessment
Dataset: MTB selected expert reassessment
46 Count (expert-concordant variants)
count · unknown

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Historical MTB agreement with expert oncogenicity reassessment

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, validation data set, paragraph ending 46/135; Figure 4A
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Guideline SOP variants
Dataset: Guideline SOP variants
81% Accuracy
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Guideline SOP variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Guideline SOP variants
Dataset: Guideline SOP variants
83% Recall (class: benign)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Guideline SOP variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, benign_sensitivity; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Guideline SOP variants
Dataset: Guideline SOP variants
83.1% Accuracy (variant type: missense)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Guideline SOP variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, missense_accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Guideline SOP variants
Dataset: Guideline SOP variants
82% Accuracy (gene role: oncogene)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Guideline SOP variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, oncogene_accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Guideline SOP variants
Dataset: Guideline SOP variants
88% Recall (class: oncogenic)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Guideline SOP variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, oncogenic_sensitivity; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configurationProtocol: OncoVI three-class assessment: Guideline SOP variants
Dataset: Guideline SOP variants
0.87 Correlation (correlation type not stated)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

OncoVI: Guideline SOP variants

Not reported

Aggregation: Not reported

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Figure 2B, concordant variants only

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Methods and evaluation design

Procedure, tasks and evaluated configurations

Evaluation design

Benchmarks bring together tasks and protocols. A task describes the biological question; a protocol defines a particular test.

These source-backed links do not make different protocols or scores interchangeable.

Baseline coverage

Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.

0 of 8 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.

Baseline status by linked protocol

Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)

Coverage is derived from release 2026-11-21-c8bea25e5abb. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.

Run this benchmark

Choose a concrete protocol before running an evaluation. Its inputs, split and scoring rules determine which results can be compared.

Run instructions

No runnable recipe has been reviewed for this benchmark. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID uc-clinical-20260930-benchmark-oncovi-study.

Source locator: Results and Figures2–4; ClinVar assessment

Related records

Suggest a correction